Uncategorized

[Nature Reviews Gastroenterology & Hepatology] Expanding preclinical and clinical literature from PDAC and other oncological indications identifies novel approaches through which radiation therapy–immunotherapy combinations could improve local and systemic disease control in patients with PDAC.

[Nature Genetics] Single-cell master regulator analysis of multiple pancreatic ductal adenocarcinoma cohorts identified malignant cells in three co-existing, molecularly distinct developmental lineage states, with distinct histopathological morphologies and spatial architecture.

[US FDA] The US FDA approved Rasonque (daraxonrasib), a RAS inhibitor for the most common form of pancreatic cancer—delivering a new treatment option to patients with advanced pancreatic cancer months ahead of schedule.

[Emmaus Life Sciences, Inc.] Emmaus Life Sciences, Inc. announced that it has entered into an exclusive option agreement with Cedars-Sinai to continue investigating the clinical utility of L-glutamine oral powder in combination with chemotherapy, as a potential treatment for PDAC.

[Oncogene] Using a transgenic mouse model, researchers showed that early stages of neuroendocrine prostate cancer are associated with increased intraprostatic recruitment of Ly6G+ polymorphonuclear neutrophils and reduced infiltration of CD8+ T cells.

[UCLA Samueli School of Engineering] The US Department of Defense has awarded a four-year, $2.1 million grant to a research team led by Dr. Neil Lin at the UCLA Samueli School of Engineering. The funding will support a new approach merging genetic testing, functional drug-sensitivity testing and advanced computer modeling into a single system for guiding prostate cancer therapy.

[Signal Transduction and Targeted Therapy] The authors provide a comprehensive overview of T cell replenishment in homeostasis, followed by the molecular hallmarks and signaling pathways of T cell senescence and exhaustion.

[Nature Cell Biology] Researchers compared fibroblast diversity and epithelial–stromal interactions in pancreatitis and PDAC using human samples, mouse models, and mouse pancreatitis-derived epithelial organoids.

[Cell Death & Disease] Researchers identified p38α (MAPK14) as a central regulator of mitophagy during severe acute pancreatitis progression (SAP). Combining bioinformatic screening with an experimental SAP model, they demonstrated aberrantly hyperactivated p38α in pancreatic acinar cells.

[Cell Death Discovery] Investigators reported that the glutamine synthesis pathway is required for cellular dormancy under androgen-deprived conditions. The key enzyme, glutamine synthetase, is upregulated during hormonal therapy, which leads to overabundant glutamine as a nutrient and an energy storage for tumor recurrence.

[Molecular Oncology] Scientists developed a CDK2 inhibitor-resistant CRPC model and performed a rational compound screen to assess which of the currently used anti-CRPC treatments could augment CDK2 therapy-response.

[Cancer Immunology Research] Researchers fabricated a targeted nanoplatform (CuS@MYC-PEG-FA) to achieve a synergistic cuproptosis and immunotherapy. The results showed that the combination of CuS@MYC-PEG-FA and PD-L1 inhibitor treatment can significantly inhibit the development of prostate cancer.